OncoImmunology

OncoImmunology is an open access journal of tumour immunology and cancer immunotherapy, published by Taylor & Francis, launched in 2012 under Landes Bioscience and carrying a 2025 Journal Impact Factor of 6.2.《肿瘤免疫学》（OncoImmunology）是一本开放获取期刊，聚焦肿瘤免疫与癌症免疫治疗，由（Taylor & Francis）出版，2012 年在（Landes Bioscience）旗下创刊，2025 年期刊影响因子为 6.2。

Scope

• The journal describes itself as a high-profile outlet broadly covering tumour immunology and immunotherapy, aiming to publish rigorous research on all aspects of basic and applied tumour immunology.期刊自述为高关注度的发表平台，广泛覆盖肿瘤免疫与免疫治疗，力求刊载基础与应用肿瘤免疫学各方面的严谨研究。
• Basic and translational studies of the immunology of solid tumours and haematological malignancies form the core of the content.实体瘤与血液系统恶性肿瘤免疫学的基础与转化研究构成内容核心。
• Inflammation and both innate and acquired immune responses against cancer are treated as standing themes.炎症以及针对癌症的固有免疫与获得性免疫应答被列为常设主题。
• Mechanisms of cancer immunoediting and of immune evasion are covered in their own right, reflecting the journal's interest in how tumours escape control.癌症免疫编辑与免疫逃逸机制单独成类，体现期刊对肿瘤如何摆脱免疫控制的关注。
• Modern immunotherapies are a major focus, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell and macrophage engagers, and CAR T cells.现代免疫治疗是主要焦点，涵盖免疫调节剂、免疫检查点抑制剂、T 细胞与 NK 细胞及巨噬细胞衔接分子以及 CAR T 细胞。
• The immunological effects of conventional anticancer therapies are also in scope, so that chemotherapy and radiotherapy are examined for their immune consequences.传统抗癌疗法的免疫学效应同样在范围内，化疗与放疗的免疫后果因而成为考察对象。
• Article types are research articles, review articles, brief reports, trial watches, article commentaries and editorials, with trial watches commissioned on an invitation-only basis and case reports or bibliometric analyses not accepted.文章类型包括研究论文、综述、简报、试验观察、文章评论与社论，其中试验观察仅接受编辑约稿，不收病例报告与文献计量分析。

History

• The first volume appeared in 2012 under Landes Bioscience of Austin, Texas, and ran to nine issues within that year.首卷于 2012 年在得克萨斯州奥斯汀的（Landes Bioscience）旗下问世，当年即出满九期。
• From volume 2 in 2013 the journal settled into a monthly rhythm of twelve issues a year, which held through volume 8 in 2019.自 2013 年第 2 卷起转为月刊，每年十二期，此节奏延续至 2019 年第 8 卷。
• Taylor & Francis acquired Landes Bioscience in June 2014, and the title passed to Taylor & Francis together with the rest of the Landes list.（Taylor & Francis）于 2014 年 6 月收购（Landes Bioscience），本刊随（Landes Bioscience）其余期刊一并转入（Taylor & Francis）。
• From volume 9 the journal moved to continuous publication, issuing one volume a year with all papers in a single issue, so that volume 15 covers 2026.自第 9 卷起改为连续出版，每年一卷且全部论文归入同一期号，2026 年对应第 15 卷。
• Publication is fully open access, normally under CC BY or CC BY-NC, with an article publishing charge of 3,300 US dollars or 2,640 pounds.刊物完全开放获取，通常采用 CC BY 或 CC BY-NC 许可，文章处理费为 3,300 美元或 2,640 英镑。
• The Journal Impact Factor stood at 8.11 in 2021, 7.723 in 2022, 6.3 in 2024 and 6.2 in 2025, while the 2025 CiteScore reached 12.1 on about 1.6 million annual downloads.影响因子 2021 年为 8.11、2022 年为 7.723、2024 年为 6.3、2025 年为 6.2，2025 年 CiteScore 达 12.1，年下载量约 160 万次。

Editors

• Lorenzo Galluzzi of the Fox Chase Cancer Center in Philadelphia and Lorenzo Falchi of Memorial Sloan Kettering Cancer Center in New York serve as Editors-in-Chief.主编为费城（Fox Chase Cancer Center）的 Lorenzo Galluzzi 与纽约（Memorial Sloan Kettering Cancer Center）的 Lorenzo Falchi。
• Galluzzi is also listed as a founding editor alongside Guido Kroemer of the University of Paris Descartes and Laurence Zitvogel of INSERM and Institut Gustave Roussy.Galluzzi 同时被列为创刊编辑，另两位创刊编辑是（University of Paris Descartes）的 Guido Kroemer 与（INSERM）及（Institut Gustave Roussy）的 Laurence Zitvogel。
• Two associate editors handle manuscripts, Giuseppe Gritti of ASST Papa Giovanni XXIII in Bergamo and Antoni Celia Terrassa of the Hospital del Mar Research Institute in Barcelona.两位副编辑负责稿件处理，即贝加莫（ASST Papa Giovanni XXIII）的 Giuseppe Gritti 与巴塞罗那（Hospital del Mar Research Institute）的 Antoni Celia Terrassa。
• The editorial board of more than fifty researchers includes James P. Allison, Lieping Chen, Padmanee Sharma, Jedd D. Wolchok, Shimon Sakaguchi, Michel Sadelain, Antoni Ribas, Ignacio Melero and Weiping Zou.五十余人的编辑委员会包括 James P. Allison、Lieping Chen、Padmanee Sharma、Jedd D. Wolchok、Shimon Sakaguchi、Michel Sadelain、Antoni Ribas、Ignacio Melero 与 Weiping Zou。
• Review is single-anonymized, and the journal states that it accepts neither case reports nor bibliometric analyses, while trial watches are commissioned by the editors only.评审采用单向匿名方式，期刊明确不收病例报告与文献计量分析，试验观察一栏仅由编辑约稿。
• Reported speed is 3 days to a first decision, 46 days to a first post-review decision and 11 days from acceptance to online publication, with an acceptance rate of 11%.官方公布初审中位 3 天、外审后首次决定 46 天、录用至上线 11 天，录用率 11%。